Results 161 to 170 of about 2,098 (178)
Some of the next articles are maybe not open access.
Idarucizumab for dabigatran overdose
Clinical Toxicology, 2016An overdose of oral anticoagulants represents a challenging scenario for emergency physicians. Dabigatran, an oral direct thrombin inhibitor, is increasingly used in place of warfarin. The lack of an antidote is a concern in patients who overdose on dabigatran, even though the drug can be eliminated with hemodialysis.
Laurens Liesenborghs +7 more
openaire +3 more sources
Idarucizumab (Praxbind) Formulary Review
Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine, 2016Idarucizumab (Praxbind), a humanized monoclonal antibody fragment was granted accelerated approval from the Food and Drug Administration in October 2015 as the first agent to reverse the effects of a novel oral anticoagulant. The drug is indicated for dabigatran reversal in patients requiring emergency surgery/urgent procedures or with life-threatening
Jean M. Connors +2 more
openaire +2 more sources
Incomplete dabigatran reversal with idarucizumab
Clinical Toxicology, 2017With increasing use of direct oral anticoagulants (DOACs), urgent reversal of these agents becomes a growing concern. Idarucizumab is a humanized monoclonal antibody fragment that specifically binds to dabigatran with higher affinity than thrombin, rapidly neutralizing its anticoagulant effect without increased risk of thrombosis.We describe two cases ...
Aaron P. Steele +2 more
openaire +3 more sources
Idarucizumab for Reversal of Dabigatran-Associated Anticoagulation
Annals of Pharmacotherapy, 2016Objective: To review clinical data on idarucizumab for the reversal of dabigatran-associated anticoagulation. Data Sources: Articles for this review were identified via PubMed using the MeSH term dabigatran combined with the keyword idarucizumab. Additional online searches via PubMed and Google Scholar were conducted for both prescribing and cost ...
Kristin Medeiros +4 more
openaire +3 more sources
Assessment of patients post reversal with idarucizumab
Journal of Thrombosis and Thrombolysis, 2018Idarucizumab, a fully humanized Fab antibody fragment, is indicated for reversal of dabigatran's anticoagulant activity. Idarucizumab neutralizes the anticoagulant effects of dabigatran by binding to dabigatran and its metabolite. In the full analysis of 503 patients, idarucizumab fully reversed the anticoagulant effect of dabigatran in more than 98 ...
Veronica Raco, Tania Ahuja, David Green
openaire +3 more sources
Idarucizumab: What Should We Know?
Current Drug Targets, 2018Idarucizumab, a humanized monoclonal antibody fragment acting as a specific antidote for dabigatran, is approved for reversing the dabigatran-associated possible bleeding from critical sites or bleeding persisting despite local post-procedure haemostasis.
Cortese F. +9 more
openaire +5 more sources
Reversal of dabigatran by idarucizumab: when and how?
Expert Review of Hematology, 2016Anticoagulants are highly effective in reducing the risk of embolism in patients with atrial fibrillation and in the treatment of venous thromboembolism. However, interfering with the coagulation system increases the risk of bleeding. Non-vitamin K oral anticoagulants (NOACs) are associated with a reduced risk of major and life-threatening bleeding ...
Peter Verhamme +2 more
openaire +2 more sources
Idarucizumab: First Global Approval
Drugs, 2015Idarucizumab (Praxbind(®)) is a fully humanized, monoclonal antibody fragment developed by Boehringer Ingelheim as a specific antidote to reverse the anticoagulant effect of the direct oral thrombin inhibitor dabigatran etexilate (Pradaxa(®)). Idarucizumab received its first global approval, in the USA, in October 2015 for use in adult patients treated
openaire +3 more sources
Dabigatran reversal with idarucizumab prior to lung transplantation
Clinical Transplantation, 2020AbstractBackgroundWhen the transplant candidates are receiving oral anticoagulation therapy before transplantation, it is crucial to have an urgent reversal strategy to prevent hemorrhagic complications perioperatively. The aim of this study was to present the experience with idarucizumab to reverse the anticoagulant activity of dabigatran prior to ...
Takashi Harano +3 more
openaire +3 more sources
Repeated Administration of Idarucizumab to a Patient with Dabigatran Overdose
Hämostaseologie, 2018SummaryIdarucizumab is designed to reverse the anticoagulant effect of dabigatran. This case report describes the administration of three independent doses of idarucizumab to a 76-year-old man suffering from atrial flutter being treated with dabigatran to prevent ischaemic stroke.
Alena Lavičková +2 more
openaire +3 more sources